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Summary Recent studies suggest that astroglia, a major non-neuronal cell type in the central
nervous system, actively participate in synaptic activity and potentially contribute to neurolo-
gical disorders including chronic pain. Astroglia exhibit a hyperactive phenotype, also referred to
as reactive astrocytosis, in response to peripheral injury. This process is often referred to as
astroglial activation. By immunostaining against glial fibrillary acidic proteins, an intermediate
cytoskeleton filament protein selectively localized to matured astrocytes, hypertrophy of
astrocytes are clearly visible in the spinal cord dorsal horn and spinal trigeminal nucleus following
a variety of injuries. Injury-related astroglial activation correlates with behavioral hyperalgesia
and conversely, astroglial inhibition attenuates pain hypersensitivity. Astrocytes have a close
anatomical relationship with neurons. Interactions between astrocytes and neurons contribute to
the mechanisms of chronic pain. Astroglial activation is accompanied by initiation of cellular
signal transduction pathways that lead to transcriptional gene regulation and release of a variety
of chemical mediators or gliotransmitters, down-regulation of glutamate transporter activity
that directly affects synaptic transmission, changes in gap junction proteins by which calcium
waves spread, and alterations of the blood brain barrier. These coordinated changes in astroglial
functions in turn modulate neuronal activity and facilitate pain transmission.
# 2009 Japanese Association for Dental Science. Published by Elsevier Ireland. All rights reserved.
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journal homepage: www.elsev ier .com/ locate / jdsrAstroglia is a major non-neuronal cell type in the central
nervous system (CNS). Morphologically, astroglia are stel-
late-shaped (star) and can be classified into protoplasmic
and fibrous astrocytes. Protoplasmic astrocytes are found in
grey matter and have many branching processes whose small
terminals (end-feet) enwrap neuronal somata, dendrites and
synapses. Fibrous astrocytes are localized in white matter and
have long unbranched processes, the tip of which may form* Correspondence address: Dental-8 South, Dept. NPS/Rm 8205,
650 W. Baltimore St., Baltimore, MD 21201-1586, USA.
Tel.: +1 410 706 3250; fax: +1 410 706 0865.
E-mail address: kren@umaryland.edu.
1882-7616/$ — see front matter # 2009 Japanese Association for Denta
doi:10.1016/j.jdsr.2009.10.005pedicles (vascular feet) that come into contact with blood
vessels. Astrocytes interconnect by connexin 43 (Cx43), an
astrocytic gap junction protein, and form a functional syncy-
tium, a network of coupled astrocytes. It is believed that
waves of calcium ions can spread between astrocytes through
the astrocytic syncytium. Similar to other glial cell subtypes,
microglia and oligodendrocytes, astroglia have long been
thought to mainly have supportive roles in CNS neuronal
activity. Astroglia help to maintain the CNS’s extracellular
environment by scavenging ions such as potassium and neuro-
transmitters such as glutamate. Astrocytes also store glycogen
for energy metabolism, form cellular scar tissue for repairing
neural tissue damage and facilitate CNS development. Beyond
these supporting roles, however, recent studies have shed newl Science. Published by Elsevier Ireland. All rights reserved.
Astroglia and pain 87light onour understandingof astrogliabiology. Ampleevidence
suggests that astroglia actively participate in synaptic activity
[1] and potentially contribute to neurological disorders includ-
ing chronic pain [2,3].
1. Injury, astroglial activation and pain
hypersensitivity
Similar to microglia, astroglia exhibit a hyperactive pheno-
type, also referred to as reactive astrocytosis, in response to
peripheral injury. This process is often referred to as astro-
glial activation. By immunostaining against glial fibrillary
acidic proteins (GFAP), an intermediate cytoskeleton fila-
ment protein selectively localized to matured astrocytes,
hypertrophy of astrocytes are clearly visible in the spinal cord
dorsal horn following a variety of injuries including chronic
constriction injury of the sciatic nerve [4], spinal nerve
ligation [5], nerve root injury models of lumbar radiculopathy
[6], experimental bone cancer [7,8], spinal cord injury [9],
complete Freund’s adjuvant (CFA)-induced inflammation
[10], formalin-induced nociception [11], acute cardiac injury
induced by intracardial injection of formalin [12], and snake
venom-induced pain [13]. Orofacial inflammation induces
astroglial activation in the regions of the spinal trigeminal
complex with a time course correlating with hyperalgesia
[14]. Astroglial activation after peripheral injury also occurs
at multiple supraspinal levels related to pain transmission
and modulation [10,15—18].
Injury-related astroglial activation correlates with beha-
vioral hyperalgesia. Colburn et al. [19] compared the effect
of seven different nerve injuries at the L5 spinal level: spinal
nerve cryoneurolysis, spinal nerve tight ligation, dorsal root
cryoneurolysis, dorsal root tight ligation, dorsal root transec-
tion, ventral root tight ligation, and sham laminectomy/dural
incision. It was found that spinal nerve or dorsal root injury
always led to mechanical allodynia and glial activation. In
contrast, ventral root lesions did not induce hyperalgesia and
produced only sporadic glial responses. Interestingly, spinal
glial responses to dorsal root lesions were almost exclusively
astrocytic. Colburn et al. [19] concluded that astrocytic
activation was always observed following spinal nerve or
dorsal root axonal injury and reliably coexisted with the
behavioral response.
Targeted expression of chemical mediators in astrocytes
through genetic manipulation further supports their role in
pain and hyperalgesia. In mice in which expression of murine
tumor necrosis factor (TNF), a proinflammatory cytokine, was
targeted to astrocytes using a glial GFAP-TNF fusion gene,
mechanical allodynia was significantly enhanced after L5
spinal nerve transection [20]. In mice overexpressing CC che-
mokine ligand 2 (CCL2 or monocyte chemoattractant protein-
1, MCP-1) in astrocytes and Schwann cells under control of
GFAP promoter, CFA induced greater edema and enhanced and
prolonged hyperalgesia when compared to control mice [21].
Astroglial inhibition attenuates pain hypersensitivity.
Fluorocitrate interrupts citric acid cycle by its inhibition of
aconitase. Although not selective against aconitase of dif-
ferent cellular origin per se, fluorocitrate selectively inhibits
the citric acid cycle of astrocytes due to a more avid uptake
by astrocytes. The subsequent energy failure results in
selective disruption of the function of astrocytes [22].Fluorocitrate has been used to assess the role of astrocytes
in pain. Intrathecal administration of fluorocitrate (1 nmol)
results in a significant attenuation of the pain hypersensitiv-
ity produced by intraplantar zymosan [23] and blocks for-
malin-induced nocifensive behavior [24]. Microinjection of
fluorocitrate into the spinal trigeminal complex (0.1—1 nmol)
attenuates masseter inflammatory hyperalgesia [14]. Injec-
tion of fluorocitrate (1—100 fmol) into the rostral ventrome-
dial medulla (RVM) reverses descending facilitation of
orofacial hyperalgesia induced by constriction injury of the
infraorbital nerve [17]. It should be noted that fluorocitrate
might also produce neuronal damage. Intrastriatal injection
of 1 nmol fluorocitrate produced ultrastructural alterations
of astrocytes without affecting neurons while a larger dose at
2 nmol also affected neuronal structures and metabolism
[25]. In the RVM, we have found that a dose 0.1 pmol is
necessary to avoid an apparent effect on neurons [17].
2. Cellular mechanisms underlying the
involvement of astroglia in pain
hypersensitivity
Astrocytes have a close anatomical relationship with neurons.
A single cortical astrocyte enwraps on an average of four
neuronal somata and contacts 300—600 neuronal dendrites
[26]. The concept of ‘‘gliapse’’ at which neuron—glial and
glia—neuronal interactions would occur was proposed in the
early 1960s to include glial cells (astrocytes) in the neuronal
network to form a fundamental functional unit of the brain
[27]. Studies have shown that synaptic strength may bemodu-
lated by gliotransmission through a ‘‘tripartite’’ synapse that
includes pre- and post-synaptic membranes and extrasynaptic
astrocytic contacts [1,28]. Most recent studies favor the view
that interactions between astrocytes and neurons contribute
to the mechanisms of synaptic plasticity and CNS disorders.
The cellular mechanisms of astrocyte—neuronal interac-
tions and contribution of astrocytes to pain hypersensitivity is
beginning to be understood. Although GFAP has been used
extensively as a marker of astroglial activation, little is known
about the functional significance of its increased expression in
astrocytes following peripheral tissue or nerve injury. Addi-
tional markers and cellular events, however, have provided
some insight. Astroglial activation is accompanied by initiation
of cellular signal transduction pathways that lead to transcrip-
tional gene regulation and release of a variety of chemical
mediators or gliotransmitters, down-regulation of glutamate
transporter activity that directly affects synaptic transmis-
sion, changes in their gap junction proteins by which calcium
waves spread, and alterations of the blood brain barrier. These
coordinated changes in astroglial functions in turn modulate
neuronal activity and facilitatepain transmission. Some recent
evidence on cellular mechanisms of a role of astroglia in pain
hypersensitivity is briefly discussed below (see Refs. [2,3,29]
for further information).
2.1. Astrocytes as a potential source of
inflammatory cytokines: role of IL-1b
The inflammatory cytokines are among a group of chemical
mediators that canbe releasedbyactivatedglia andhavebeen
implicated in persistent pain states [30]. Interleukin (IL)-1b, a
88 K. Renprototypeproinflammatory cytokine, is involved in a variety of
diseases with pain conditions such as rheumatoid arthritis,
inflammatory bowel disease, osteroarthritis, multiple sclero-
sis andneuropathy [31]. Interestingly, recent studies showthat
IL-1b is selectively induced in astrocytes in animal models of
bone cancer pain [8], masseter inflammation [14], infraorbital
nerve injury [17] and intracerebral hemorrhage [32]. These
results suggest that astrocytes are a source of secreted IL-1b
after injury. Following L5 spinal nerve injury, matrix metallo-
proteinase (MMP)-2 in astrocytes cleaves pro-IL-1b into bioac-
tive IL-1b and this event correlates with the maintenance of
neuropathic pain behavior in rats [33].
IL-1b may be a messenger of astroglia to neurons through
signal coupling with N-methyl-D-aspartate (NMDA) receptors.
IL-1 receptors colocalize with the NR1 subunit of the NMDA
receptor [14]. IL-1b enhances NMDA receptor-mediated
intracellular calcium release [34]; and facilitates inward
currents and inhibits outward currents induced by NMDA in
hippocampal neurons [35]. Direct application of IL-1b
enhances NMDA receptor phosphorylation similar to that
following tissue inflammation [14]. In primary mouse neuro-
nal cultures, IL-1b activates Src kinase that further triggers
the phosphorylation of the NMDAR NR2B subunit [36]. The IL-
1 receptor antagonist attenuates pain hypersensitivity
through preventing NMDA receptor phosphorylation in rats
[37]. Thus, astroglial activation and associated IL-1b release
play a critical role in the mechanisms of hyperalgesia. The
cellular events that lead to IL-1b release after astroglial
activation is less clear. The potential role of the inflamma-
some, amultiprotein complex thatmediates the activation of
caspase-1 that facilitates secretion of proinflammatory cyto-
kines IL-1b and IL-18, should be investigated [38].
2.2. Astrocytic MCP-1 in neuropathic pain
Monocyte chemoattractant protein-1 (MCP-1/CCL2) is a che-
mokine that is expressed in primary sensory neurons and
involved in persistent pain [39]. MCP-1 may also be present
in astrocytes [40]. Recent studies show that spinal nerve
ligation induced MCP-1 upregulation in the spinal cord, pri-
marily in spinal cord astrocytes [41]. Spinal administration of
MCP-1 neutralizing antibody attenuated neuropathic pain
and application of MCP-1 induced hyperalgesia [41]. Activa-
tion of MCP-1 is apparently down stream to c-jun-N-terminal
kinase (JNK) in spinal astrocytes [5]. Both nerve injury-
induced MCP-1 upregulation and pain were suppressed by a
JNK inhibitor, D-JNKI-1 [41]. In cultured astrocytes, TNFa
transiently activated JNK via TNF receptor-1 and induced
MCP-1 [41], suggesting an astrocytic signaling pathway invol-
ving TNF receptor-JNK-MCP-1. Interestingly, TNFa has been
shown in microglia and macrophages but is absent in astro-
cytes; and the MCP-1 receptor CCR2 is localized in microglia/
neuron, but not in astrocytes [41,42]. MCP-1 potentiates
NMDA- and AMPA-induced currents in spinal dorsal horn
neurons [41]. These findings suggest interactions between
microglia and astroglia and neuron and glia.2.3. NFkB in astrocytes
Nuclear factor kappa-B (NFkB) is a transcription factor that
regulates transcription of a variety of genes includinginflammatory cytokines and chemokines in glia. A common
downstream event of IL-1R/toll-like receptor (TLR) signaling
is phosphorylation of the NFkB subunit followed by its trans-
location to the nucleus. The activation of NFkB is preceded
by phosphorylation of inhibitory kappa-B (IkB) induced by
cytokines. As a mechanism of feedback control of NFkB
activity, IkB is also upregulated upon NFkB activation.
IkBamRNA expression was markedly induced in the spinal
cord, mainly in astrocytes and endothelial cells, following
intrathecal administration of the human immunodeficiency
virus-1 envelope glycoprotein, gp120 [43]. Intrathecal
administration of NFkB inhibitors partially attenuated
gp120-induced allodynia and reversed pain hypersensitivity
induced by sciatic nerve inflammation [43]. IL-18R is upre-
gulated in spinal astrocytes after nerve injury and the func-
tional inhibition of IL-18 signaling pathways suppressed nerve
injury-induced allodynia and decreased the phosphorylation
of NFkB in astrocytes and the induction of astroglial markers
[44]. Recent studies have shown that low levels of activity of
catechol-O-methyltransferase (COMT), an enzyme involved
in catecholamines metabolism is related to pain hypersensi-
tivity [45]. This altered pain may be related to NFkB-
mediated inhibition of COMT expression in astrocytes [46].
These findings suggest that the increased NFkB transcrip-
tional activity in astrocytes may underlie molecular mechan-
isms of pain hypersensitivity.
2.4. Astrocytic gap junction proteins
Communication between astrocytes can be mediated by
specific gap junction proteins, which spread calcium waves
between astrocytes after stimulation and may also convey
astrocyte-to-neuron signaling [47]. The gap junction may
play a role in spinal nociceptive processing [48]. Spataro
et al. [49] showed that intrathecal administration of the
gap junction decoupler carbenoxolone reversedmirror image
mechanical allodynia after nerve injury, while leaving ipsi-
lateral mechanical allodynia unaffected, suggesting that
spinal gap junctions are potentially involved in spread of
pain facilitation. Following masseter muscle inflammation,
astrocytic gap junction protein connexin 43 (Cx43) was upre-
gulated in astrocytes in the subnuclei interpolaris/caudalis
(Vi/Vc) trigeminal transition zone, a subregion of the spinal
trigeminal complex involved in trigeminal pain processing
[14]. Cx43 also increased in the trigeminal ganglion satellite
glial cells in rats with chronic constriction injury of the
infraorbital nerve [50]. Injection of gap junction decouplers
into the Vi/Vc site attenuated masseter hyperalgesia/allo-
dynia after inflammation (Wang et al., unpublished observa-
tion). Sciatic nerve stimulation led to an increase in Cx43
dephosphorylation in the spinal cord dorsal horn [51], sug-
gesting that neural input can regulate gap junctional cou-
pling between astrocytes. Cx43 dephosphorylation may
counter phosphorylation-related inhibition of gap junction
channel communication [52].
The involvement of astrocytic gap junction proteins in
pain facilitation may be understood by their role in inter-
astrocytic cellular communication, which is accomplished by
direct exchange of small molecules. A particular relevant
phenomenon is that the calcium surge in astrocytes can
propagate through gap junctions [47]. This apparent calcium
signaling between astrocytes, however, is mainly observed in
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tions is unclear. Recent two-photon microscopy studies sug-
gest that the spread of calcium waves between astrocytes is
limited, most likely only involving immediate neighboring
astrocytes [53]. Other signaling molecules such as IP3 may
also diffuse through astrocytic gap junctions to spread exci-
tation [1]. Nevertheless, there is a positive correlation
between coordination of calcium activity in neighboring
astrocytes and neuronal discharge [53], supporting a role
of astrocytic gap junction proteins in neuronal hyperexcit-
ability and enhanced astrocytic activity after injury.
2.5. Excitatory and inhibitory amino acids
transporters
Astrocytic glutamate transporters (mainly GLT-1) uptake
glutamate into astrocytes to help to maintain an appropriate
level of extracellular glutamate concentration. Models of
neuropathic pain have been associated with a decrease in
GLT-1 expression ([3], Review). Presumably, a reduction in
GLT-1 activity may lead to a build up of glutamate concen-
tration in the synaptic cleft, leading to neuronal hyperexcit-
ability and hyperalgesia. Interestingly, the often-used glial
modulator/inhibitor propentofylline produces multiple
effects on astrocytes. In primary astrocytic cultures that
exhibit an activated phenotype, propentofylline suppresses
lipopolysaccharide (LPS)-induced chemokine release but
induces GLT-1 expression and glutamate uptake [54]. Pro-
pentofylline may also be able to restore glutamate transpor-
ter activity in vivo. In transgenic mice with double transgenic
GLT-1-enhanced green fluorescent protein/GLAST-Discosoma
Red promoter, propentofylline reversed the reduced promo-
ter activation in the spinal dorsal horn after spinal nerve
injury [55]. These cellular actions of propentofylline are
consistent with its anti-allodynic effect [56].
Expression of astrocytic GLT-1 is regulated by neuronal
activity. Transcriptional activation of GLT-1 depends on neu-
ron-stimulated kappa B-motif binding phosphoprotein (KBBP)
that binds the GLT-1 promoter [57]. Nervous tissue injury
reduced astroglial KBBP expression and led to transcriptional
dysfunction of astroglial transporter expression [57].
Astrocytes are also responsible for removing gamma-ami-
nobutyric acid (GABA), an inhibitory amino acid transmitter,
after its release from GABAergic presynaptic terminals. High
affinity GABA transporters are localized in astrocytes. After
facial inflammation, the GABA transporter GAT immunoreac-
tivity increased in glial cells in the spinal trigeminal nucleus
on the side of injury [58]. Thus, the GABA transporter changes
in the opposite direction after injury compared to glutamate
transporters. The increased expression of GAT may facilitate
removal of GABA and lead to a reduced GABAergic inhibition.
This effect is consistent with central hyperexcitability and
hyperalgesia after tissue injury.
2.6. Astroglial glutamate—glutamine shuttle
After being taken up by astrocytes, glutamate is converted to
glutamine. Glutamine is then transported back to presynap-
tic terminals where it is converted to glutamate to replenish
the transmitter pool. While this astroglial glutamate—gluta-
mine shuttle is critical in maintaining normal synapticexcitability, hyperactivity of the shuttle may contribute to
increased pain. Inhibition of the astrocytic glutamine shuttle
by application of methionine sulfoximine, an inhibitor of
astroglial glutamine synthetase that catalyzes conversion
of glutamate to glutamine, hyperexcitability of trigeminal
nociceptive neurons is attenuated [59]. Consistently, inhibi-
tion of presynaptic uptake of glutamine by the neuronal
system A transporter suppressed mustard-oil-induced sensi-
tization of medullary dorsal horn nociceptive neurons [60].
These effects are likely a result of reduced supply of gluta-
mate neurotransmitters due to inhibition of the astroglial
glutamate—glutamine shuttle.
2.7. D-Serine
Astrocytes may release so called gliotransmitters to affect
neuronal activity and it has now been recognized that neu-
rotransmission is not the only form of signal transmission in
the brain. Glutamate may be released from astrocytes
through exocytosis, although the specific mechanisms are
still unclear [1]. Glial-derived glutamate may have an impact
on neuronal hyperexcitability through an effect on extrasy-
naptic NMDA receptors [28]. However, recent work suggests
that calcium-dependent glutamate release from astrocytes
may not directly affect neuronal activity in situ [61]. D-
Serine, a co-agonist of the NMDA receptor, may also be
released from astrocytes [62]. Intrathecal administration
of a D-serine inhibitor, D-amino acid oxygenase, attenuated
mechanical hypersensitivity induced by titanic sciatic stimu-
lation [63]. The role of astroglia-derived excitatory amino
acids to central sensitization and hyperalgesia should be
further studied.
2.8. Calcium-binding proteins in astrocytes
S100b is a calcium-binding peptide produced mainly by
astrocytes. Astrocytic localization of S100b is limited to
the soma, which is distinctly different from widespread
distribution of GFAP in branches and cell body of astrocytes.
About 30—40% of the S100b immunoreactivity overlaps with
GFAP [15,64] and can be used as an alternative functional
marker of astroglial activity. S100b mRNA and protein levels
are upregulated in the spinal cord after hind paw inflamma-
tion, L5 spinal nerve ligation and spinal cord injury
[10,64,65]. The increased GFAP immunoreactivity in rostral
ventromedial medulla after injury of the infraorbital nerve is
accompanied by an increase in S100b immunoreactivity [17].
The pain hypersensitivity induced by nerve injury is attenu-
ated in S100b knockout mice and enhanced in S100b expres-
sing animals [64]. These findings support a role of enhanced
astroglial activity in the development of persistent pain.
2.9. Endothelin B receptors
Astrocytes express endothelin B (ETB) receptors [66,67], a
subtype of G protein-linked receptors mediating effects of
endothelins. After compression injury of the spinal cord, the
ETB receptor immunoreactivity is increased in both proto-
plasmic and fibrous astrocytes, which coincides with upre-
gulation of GFAP, or astroglial activation [66]. Interestingly,
the upregulation of ETB receptors appears selective in
90 K. Renastrocytes since the ETB receptor immunoreactivity is
reduced in ependymal cells and does not change in vascular
endothelial cells. The increased ETB receptor function after
injury is consistent with a role of endothelins in astroglial
responses to injury. Application of endothelin-1 induces
hypertrophy of astrocytes in the normal optic nerve and
the ET receptor antagonist blocks hypertrophy of astrocytes
in the crushed optic nerve [67]. Endothelin-1 also affects
S100b expression in astrocytes [68]. Since endothelins can be
secreted from vascular endothelial cells, they are likely
hematogenous messengers that bind to ETB receptors on
astrocytes and contribute to astroglial activation after injury.
2.10. Blood brain barrier
Astrocytes have contact with brain blood vessels via their
end-feet and processes and play an important role in main-
taining normal function of the blood brain barrier (BBB),
although in most vertebrates, the principal anatomic site
of the BBB is located within the endothelium ([69], review).
The BBB permeability is apparently increased after nerve
injury and peripheral inflammation, which is correlated with
astroglial activation and pain hypersensitivity [70,71]. The
water channel protein aquaporin-4 is distributed in the end-
foot membrane of astrocytes to mediate water movements
between brain cellular compartments including interstitial
and vascular spaces and contributes to the maintenance of
BBB properties. The aquaporin-4 mRNA is upregulated in the
spinal cord after spinal cord injury and central neuropathic
pain [65]. It is likely that astroglial activity plays a role in
perturbed BBB function that may precipitate brain responses
to injury and pain hypersensitivity.
Recognition of the contribution of astroglia and their
interactions with neurons to pain hypersensitivity prompts
new treatment for chronic pain conditions. In addition to
direct inhibition of neuronal activity, a variety of non-neu-
ronal components of the brain may now also be targeted for
pain relief. It is hoped that more selective agents that block
astroglial activation after injury will soon be developed and
proven effective in treating chronic pain.
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